CN116133692A - 治疗突变淋巴瘤的方法 - Google Patents

治疗突变淋巴瘤的方法 Download PDF

Info

Publication number
CN116133692A
CN116133692A CN202180062152.2A CN202180062152A CN116133692A CN 116133692 A CN116133692 A CN 116133692A CN 202180062152 A CN202180062152 A CN 202180062152A CN 116133692 A CN116133692 A CN 116133692A
Authority
CN
China
Prior art keywords
compound
pharmaceutically acceptable
acceptable salt
administered
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180062152.2A
Other languages
English (en)
Chinese (zh)
Inventor
D·沃克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kemela Medical Co
Original Assignee
Kemela Medical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kemela Medical Co filed Critical Kemela Medical Co
Publication of CN116133692A publication Critical patent/CN116133692A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
CN202180062152.2A 2020-07-30 2021-07-29 治疗突变淋巴瘤的方法 Pending CN116133692A (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202063058891P 2020-07-30 2020-07-30
US63/058,891 2020-07-30
US202063109854P 2020-11-04 2020-11-04
US63/109,854 2020-11-04
US202163202242P 2021-06-02 2021-06-02
US63/202,242 2021-06-02
PCT/US2021/071048 WO2022027058A1 (en) 2020-07-30 2021-07-29 Methods of treating mutant lymphomas

Publications (1)

Publication Number Publication Date
CN116133692A true CN116133692A (zh) 2023-05-16

Family

ID=80036177

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180062152.2A Pending CN116133692A (zh) 2020-07-30 2021-07-29 治疗突变淋巴瘤的方法

Country Status (13)

Country Link
US (2) US11857535B2 (https=)
EP (1) EP4188374A4 (https=)
JP (1) JP2023536462A (https=)
KR (1) KR20230044480A (https=)
CN (1) CN116133692A (https=)
AU (1) AU2021316053A1 (https=)
BR (1) BR112023001638A2 (https=)
CA (1) CA3187255A1 (https=)
IL (1) IL300175A (https=)
MX (1) MX2023001217A (https=)
PH (1) PH12023550237A1 (https=)
TW (1) TW202220653A (https=)
WO (1) WO2022027058A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL315310A (en) 2017-12-26 2024-10-01 Kymera Therapeutics Inc Irak degraders and uses thereof
CA3119773A1 (en) 2018-11-30 2020-06-04 Kymera Therapeutics, Inc. Irak degraders and uses thereof
PH12022500002A1 (en) 2019-06-28 2023-04-03 Kymera Therapeutics Inc Irak degraders and uses thereof
WO2021011868A1 (en) 2019-07-17 2021-01-21 Kymera Therapeutics, Inc. Irak degraders and uses thereof
WO2021119159A1 (en) 2019-12-10 2021-06-17 Kymera Therapeutics, Inc. Irak degraders and uses thereof
KR20220145325A (ko) 2019-12-17 2022-10-28 카이메라 쎄라퓨틱스 인코포레이티드 Irak 분해제 및 이의 용도
CN116867758A (zh) 2020-12-30 2023-10-10 凯麦拉医疗公司 Irak降解剂和其用途
US20240383887A1 (en) * 2021-05-07 2024-11-21 Kymera Therapeutics, Inc. Deuterated irak degraders and uses thereof
CA3243560A1 (en) 2022-01-31 2023-08-03 Kymera Therapeutics, Inc. Iraqi Degradation Agents and Their Uses
WO2024073507A1 (en) 2022-09-28 2024-04-04 Theseus Pharmaceuticals, Inc. Macrocyclic compounds and uses thereof
CN115572768B (zh) * 2022-11-04 2023-12-19 山东第一医科大学附属省立医院(山东省立医院) 一种针对弥漫大b细胞淋巴瘤的预后评估及联合治疗
WO2024148049A1 (en) * 2023-01-04 2024-07-11 Kymera Therapeutics, Inc. Irak4 degraders and uses thereof
WO2024191788A1 (en) * 2023-03-10 2024-09-19 Kymera Therapeutics, Inc. Irak4 degraders and uses thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190192668A1 (en) * 2017-12-26 2019-06-27 Kymera Therapeutics, Inc. Irak degraders and uses thereof
WO2019160915A1 (en) * 2018-02-14 2019-08-22 Dana-Farber Cancer Institute, Inc. Irak degraders and uses thereof
WO2020092907A1 (en) * 2018-11-02 2020-05-07 Dana-Farber Cancer Institute, Inc. Acetylation writer inhibitor development and uses thereof
WO2021127190A1 (en) * 2019-12-17 2021-06-24 Kymera Therapeutics, Inc. Irak degraders and uses thereof

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2382377T3 (es) 2003-05-30 2012-06-07 Gemin X Pharmaceuticals Canada Inc. Compuestos triheterocíclicos, composiciones, y métodos para tratar cáncer
TWI380996B (zh) 2004-09-17 2013-01-01 Hoffmann La Roche 抗ｏｘ４０ｌ抗體
PT2343320T (pt) 2005-03-25 2018-01-23 Gitr Inc Anticorpos anti-gitr e as suas utilizações
PL1888550T3 (pl) 2005-05-12 2014-12-31 Abbvie Bahamas Ltd Promotory apoptozy
PT1907424E (pt) 2005-07-01 2015-10-09 Squibb & Sons Llc Anticorpos monoclonais humanos para o ligando 1 de morte programada (pd-l1)
WO2008118802A1 (en) 2007-03-23 2008-10-02 Regents Of The University Of Minnesota Therapeutic compounds
EP1987839A1 (en) 2007-04-30 2008-11-05 I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
US8591886B2 (en) 2007-07-12 2013-11-26 Gitr, Inc. Combination therapies employing GITR binding molecules
EP2044949A1 (en) 2007-10-05 2009-04-08 Immutep Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response
US10047066B2 (en) 2007-11-30 2018-08-14 Newlink Genetics Corporation IDO inhibitors
CA2722159C (en) 2008-04-24 2016-04-05 Newlink Genetics Corporation Substituted phenylimidazole compounds and their use as ido inhibitors
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
EP3255060A1 (en) 2008-12-09 2017-12-13 F. Hoffmann-La Roche AG Anti-pd-l1 antibodies and their use to enhance t-cell function
US8921037B2 (en) 2008-12-16 2014-12-30 Bo Han PF4-depleted platelet rich plasma preparations and methods for hard and soft tissue repair
KR101790802B1 (ko) 2009-09-03 2017-10-27 머크 샤프 앤드 돔 코포레이션 항-ｇｉｔｒ 항체
EP2493862B1 (en) 2009-10-28 2016-10-05 Newlink Genetics Corporation Imidazole derivatives as ido inhibitors
ES2722300T3 (es) 2009-12-10 2019-08-09 Hoffmann La Roche Anticuerpos que se unen preferentemente al dominio extracelular 4 de CSF1R y su uso
EP2542256B1 (en) 2010-03-04 2019-05-22 MacroGenics, Inc. Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
US9169323B2 (en) 2010-03-05 2015-10-27 Hoffmann-La Roche Inc. Antibodies against human CSF-1R
JP5989547B2 (ja) 2010-03-05 2016-09-07 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト ヒトｃｓｆ−１ｒに対する抗体及びその使用
HRP20190047T1 (hr) 2010-05-04 2019-02-22 Five Prime Therapeutics, Inc. Protutijela koja se vežu na csf1r
MX337040B (es) 2010-09-09 2016-02-09 Pfizer Moleculas de union a 4-1bb.
NO2694640T3 (https=) 2011-04-15 2018-03-17
JP6072771B2 (ja) 2011-04-20 2017-02-01 メディミューン，エルエルシー Ｂ７−ｈ１およびｐｄ−１に結合する抗体およびその他の分子
KR101764096B1 (ko) 2011-11-28 2017-08-02 메르크 파텐트 게엠베하 항-ｐｄ-ｌ1 항체 및 그의 용도
RU2658603C2 (ru) 2011-12-15 2018-06-21 Ф.Хоффманн-Ля Рош Аг Антитела против человеческого csf-1r и их применения
KR20140127855A (ko) 2012-02-06 2014-11-04 제넨테크, 인크. Csf1r 억제제를 사용하는 조성물 및 방법
AR090263A1 (es) 2012-03-08 2014-10-29 Hoffmann La Roche Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
RU2670743C9 (ru) 2012-05-11 2018-12-19 Файв Прайм Терапьютикс, Инк. Способы лечения состояний антителами, которые связывают рецептор колониестимулирующего фактора 1 (csf1r)
UY34887A (es) 2012-07-02 2013-12-31 Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
CN107759690A (zh) 2012-08-31 2018-03-06 戊瑞治疗有限公司 用结合群落刺激因子1受体(csf1r)的抗体治疗病状的方法
EP3710443A1 (en) 2017-11-17 2020-09-23 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of interleukin-1 receptor-associated kinase 4 polypeptides
WO2020010227A1 (en) 2018-07-06 2020-01-09 Kymera Therapeutics, Inc. Protein degraders and uses thereof
CA3119773A1 (en) 2018-11-30 2020-06-04 Kymera Therapeutics, Inc. Irak degraders and uses thereof
PH12022500002A1 (en) 2019-06-28 2023-04-03 Kymera Therapeutics Inc Irak degraders and uses thereof
US20240383887A1 (en) * 2021-05-07 2024-11-21 Kymera Therapeutics, Inc. Deuterated irak degraders and uses thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190192668A1 (en) * 2017-12-26 2019-06-27 Kymera Therapeutics, Inc. Irak degraders and uses thereof
WO2019160915A1 (en) * 2018-02-14 2019-08-22 Dana-Farber Cancer Institute, Inc. Irak degraders and uses thereof
WO2020092907A1 (en) * 2018-11-02 2020-05-07 Dana-Farber Cancer Institute, Inc. Acetylation writer inhibitor development and uses thereof
WO2021127190A1 (en) * 2019-12-17 2021-06-24 Kymera Therapeutics, Inc. Irak degraders and uses thereof

Also Published As

Publication number Publication date
US20240316004A1 (en) 2024-09-26
EP4188374A1 (en) 2023-06-07
US11857535B2 (en) 2024-01-02
IL300175A (en) 2023-03-01
JP2023536462A (ja) 2023-08-25
WO2022027058A1 (en) 2022-02-03
TW202220653A (zh) 2022-06-01
MX2023001217A (es) 2023-03-03
CA3187255A1 (en) 2022-02-03
EP4188374A4 (en) 2024-08-14
AU2021316053A1 (en) 2023-03-02
US20220054453A1 (en) 2022-02-24
KR20230044480A (ko) 2023-04-04
BR112023001638A2 (pt) 2023-02-23
PH12023550237A1 (en) 2024-04-29

Similar Documents

Publication Publication Date Title
US11857535B2 (en) Methods of treating mutant lymphomas
KR20230172548A (ko) Mek 억제제 및 이의 용도
US20240254120A1 (en) Ep4 inhibitors and synthesis thereof
US20260049095A1 (en) Deuterated stat3 degraders and uses thereof
CN116554168A (zh) Cxcr4抑制剂及其用途
WO2022051569A1 (en) Substituted 3-piperidinyl-pyrrolo[2,3-b]pyridines and related compounds and their use in treating medical conditions
US20240092779A1 (en) Usp1 inhibitors and uses thereof
WO2022051565A1 (en) Substituted 4-piperidinyl-quinazolines, 4-piperidinyl-pyrimidine-2-amines, and related compounds and their use in treating medical conditions
US12459895B2 (en) MEK inhibitors and uses thereof
WO2022051567A1 (en) Substituted pyrido[2,3-b]pyrazinones and reuated compounds and their use in treating medicau conditions
WO2023173053A1 (en) Mek inhibitors and uses thereof
WO2023173057A1 (en) Mek inhibitors and uses thereof
US20230233546A1 (en) Methods of treating cancer
WO2022187518A1 (en) Substituted 4-piperidinyl-imidazo[4,5-b]pyridines and related compounds and their use in treating medical conditions
WO2022187520A1 (en) Substituted 3-piperidinyl-pyrazolo[3,4-b]pyridines and related compounds and their use in treating medical conditions
CN118574613A (zh) 治疗癌症的方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20230516

WD01 Invention patent application deemed withdrawn after publication